Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > TWITTER

<< Previous

Bullboard Posts

Next >>

Post by MetzGERon Aug 02, 2021 5:02pm

174 Views

Post# 33640460

TWITTER

Conversation with jcrest:

“We live for active, inquisitive investors and are always happy to address any inquiry and critique. Things are lining up very nicely for a very busy late-2021(Sept-Dec) full of material announcements and evidence of progress made over the last few months.“

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?